1 Name
- This instrument is the National Health (Pharmaceutical benefits – early supply) Amendment Instrument 2025 (No. 1).
- This instrument may also be cited as PB 2 of 2025.
2 Commencement
- Each provision of this instrument specified in column 1 of the table commences, or is taken to have commenced, in accordance with column 2 of the table. Any other statement in column 2 has effect according to its terms.
Commencement information |
Column 1 | Column 2 | Column 3 |
Provisions | Commencement | Date/Details |
1. The whole of this instrument | 1 February 2025 | 1 February 2025 |
Note: This table relates only to the provisions of this instrument as originally made. It will not be amended to deal with any later amendments of this instrument.
- Any information in column 3 of the table is not part of this instrument. Information may be inserted in this column, or information in it may be edited, in any published version of this instrument.
3 Authority
This instrument is made under subsection 84AAA(2) of the National Health Act 1953.
4 Schedules
Each instrument that is specified in a Schedule to this instrument is amended or repealed as set out in the applicable items in the Schedule concerned, and any other item in a Schedule to this instrument has effect according to its terms.
Schedule 1—Amendments
National Health (Pharmaceutical benefits—early supply) Instrument 2015 (PB 120 of 2015)
- Schedule 1, omit entry for Alirocumab
- Schedule 1, after entry for Estradiol in the form Transdermal patches 390 micrograms, 8
insert:
| Transdermal patches 390 micrograms, 24 (S19A) | 20 | 1 | 1 | |
- Schedule 1, entry for Niraparib
omit:
| Capsule 100 mg (as tosilate monohydrate) | 20 | 56 | 2 | |
| | 20 | 56 | 5 | |
| | 20 | 84 | 2 | |
| | 20 | 84 | 5 | |
- Schedule 1, after entry for Selegiline
insert:
